Performance of probabilistic method to detect duplicate individual case safety reports.

Abstract:

BACKGROUND:Individual case reports of suspected harm from medicines are fundamental for signal detection in postmarketing surveillance. Their effective analysis requires reliable data and one challenge is report duplication. These are multiple unlinked records describing the same suspected adverse drug reaction (ADR) in a particular patient. They distort statistical screening and can mislead clinical assessment. Many organisations rely on rule-based detection, but probabilistic record matching is an alternative. OBJECTIVES:The aim of this study was to evaluate probabilistic record matching for duplicate detection, and to characterise the main sources of duplicate reports within each data set. RESEARCH DESIGN:vigiMatch™, a published probabilistic record matching algorithm, was applied to the WHO global individual case safety reports database, VigiBase(®), for reports submitted between 2000 and 2010. Reported drugs, ADRs, patient age, sex, country of origin, and date of onset were considered in the matching. Suspected duplicates for the UK, Denmark, and Spain were reviewed and classified by the respective national centre. This included evaluation to determine whether confirmed duplicates had already been identified by in-house, rule-based screening. Furthermore, each confirmed duplicate was classified with respect to the likely source of duplication. MEASURES:For each country, the proportions of suspected duplicates classified as confirmed duplicates, likely duplicates, otherwise related, and unrelated were obtained. The proportions of confirmed or likely duplicates that were not previously known by the national organisation were determined, and variations in the rates of suspected duplicates across subsets of reports were characterised. RESULTS:Overall, 2.5 % of the reports with sufficient information to be evaluated by vigiMatch were classified as suspected duplicates. The rates for the three countries considered in this study were 1.4 % (UK), 1.0 % (Denmark), and 0.7 % (Spain). Higher rates of suspected duplicates were observed for literature reports (11 %) and reports with fatal outcome (5 %), whereas a lower rate was observed for reports from consumers and non-health professionals (0.5 %). The predictive value for confirmed or likely duplicates among reports flagged as suspected duplicates by vigiMatch ranged from 86 % for the UK, to 64 % for Denmark and 33 % for Spain. The proportions of confirmed duplicates that were previously unknown to national centres ranged from 89 % for Spain, to 60 % for the UK and 38 % for Denmark, despite in-house duplicate detection processes in routine use. The proportion of unrelated cases among suspected duplicates were below 10 % for each national centre in the study. CONCLUSIONS:Probabilistic record matching, as implemented in vigiMatch, achieved good predictive value for confirmed or likely duplicates in each data source. Most of the false positives corresponded to otherwise related reports; less than 10 % were altogether unrelated. A substantial proportion of the correctly identified duplicates had not previously been detected by national centre activity. On one hand, vigiMatch highlighted duplicates that had been missed by rule-based methods, and on the other hand its lower total number of suspected duplicates to review improved the accuracy of manual review.

journal_name

Drug Saf

journal_title

Drug safety

authors

Tregunno PM,Fink DB,Fernandez-Fernandez C,Lázaro-Bengoa E,Norén GN

doi

10.1007/s40264-014-0146-y

subject

Has Abstract

pub_date

2014-04-01 00:00:00

pages

249-58

issue

4

eissn

0114-5916

issn

1179-1942

journal_volume

37

pub_type

杂志文章
  • Drug-versus-drug adverse event rate comparisons: a pilot study based on data from the US FDA Adverse Event Reporting System.

    abstract:BACKGROUND:A number of published studies compare adverse event rates for drugs on the basis of reports in the US FDA Adverse Event Reporting System (AERS). While the AERS data have the advantage of timely availability and a large capture population, the database is subject to many significant biases, and lacks complete...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.2165/00002018-200932020-00006

    authors: Hochberg AM,Pearson RK,O'Hara DJ,Reisinger SJ

    更新日期:2009-01-01 00:00:00

  • Pain treatment in multimorbid patients, the older population and other high-risk groups. The clinical challenge of reducing toxicity.

    abstract::The prevalence of pain is high in multimorbid patients and they can experience a multitude of painful conditions. The changes in physiology and homeostasis associated with multimorbidity and increasing age and the immature metabolism of neonates all increase the risk of toxicity from analgesics. Altered pharmacokineti...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-199818060-00006

    authors: Wilder-Smith CH

    更新日期:1998-06-01 00:00:00

  • Post-approval safety issues with innovative drugs: a European cohort study.

    abstract:BACKGROUND:At time of approval, knowledge of the full benefit risk of any drug is limited, in particular with regards to safety. Post-approval surveillance of potential drug safety concerns is recognized as an important task of regulatory agencies. For innovative, often first-in-class drugs, safety knowledge at time of...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.1007/s40264-013-0094-y

    authors: Mol PG,Arnardottir AH,Motola D,Vrijlandt PJ,Duijnhoven RG,Haaijer-Ruskamp FM,de Graeff PA,Denig P,Straus SM

    更新日期:2013-11-01 00:00:00

  • Safety of thrombolysis during cardiopulmonary resuscitation.

    abstract::The prognosis is generally poor for patients who experience a cardiac arrest. The most common causes of sudden cardiac arrest are massive pulmonary embolism (PE) and acute myocardial infarction (MI). While thrombolysis is a first-line treatment option in massive PE and acute MI, cardiopulmonary resuscitation (CPR) has...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-200326060-00001

    authors: Spöhr F,Böttiger BW

    更新日期:2003-01-01 00:00:00

  • The comparative efficacy and safety of the angiotensin receptor blockers in the management of hypertension and other cardiovascular diseases.

    abstract::All national guidelines for the management of hypertension recommend angiotensin receptor blockers (ARBs) as an initial or add-on antihypertensive therapy. The eight available ARBs have variable clinical efficacy when used for control of hypertension. Additive blood pressure-lowering effects have been demonstrated whe...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.1007/s40264-014-0239-7

    authors: Abraham HM,White CM,White WB

    更新日期:2015-01-01 00:00:00

  • Patient Reporting in the EU: Analysis of EudraVigilance Data.

    abstract:INTRODUCTION:New pharmacovigilance legislation was adopted in the EU in 2010 and became operational in July 2012. The legislation placed an obligation on all national competent authorities (NCAs) and marketing authorisation holders (MAHs) to record and report cases of suspected adverse drug reactions (ADRs) received fr...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.1007/s40264-017-0534-1

    authors: Banovac M,Candore G,Slattery J,Houÿez F,Haerry D,Genov G,Arlett P

    更新日期:2017-07-01 00:00:00

  • A Comparative View of Reported Adverse Effects of Statins in Social Media, Regulatory Data, Drug Information Databases and Systematic Reviews.

    abstract:INTRODUCTION:There are few studies assessing how data on adverse drug events from consumers on social media compare with other sources. AIM:The aim of this study was to assess the consistency of adverse event data of statin medications from social media as compared with other sources. METHODS:We collected data on the...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.1007/s40264-020-00998-1

    authors: Golder S,Smith K,O'Connor K,Gross R,Hennessy S,Gonzalez-Hernandez G

    更新日期:2021-02-01 00:00:00

  • Long-term treatment with atypical antipsychotics and the risk of weight gain : a literature analysis.

    abstract::The aim of this review is to analyse and summarise the literature data about the incidence of weight gain in patients exposed to atypical antipsychotics during long-term (>or=1 year) treatment regimens. Despite the clinical relevance of the topic, the vast majority of reviewed studies showed methodological limitations...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-200629040-00002

    authors: Gentile S

    更新日期:2006-01-01 00:00:00

  • Acute fluoride toxicity. Pathophysiology and management.

    abstract::Acute intoxication with inorganic fluoride disrupts numerous physiological systems. As a potent acid it acts corrosively on the skin and mucous membranes, producing severe burns. As the most electronegative element it tightly binds many cations essential to homeostasis, producing, for example, profound hypocalcaemia a...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-199005020-00001

    authors: McIvor ME

    更新日期:1990-03-01 00:00:00

  • Safety of Eosinophil-Depleting Therapy for Severe, Eosinophilic Asthma: Focus on Benralizumab.

    abstract::Eosinophils play a pivotal role in the inflammatory pathology of asthma and have been the target of new biologic treatments for patients with eosinophilic asthma. Given the central role of interleukin (IL)-5 in the eosinophil lifecycle, several therapies directed against the IL-5 pathway have been developed, including...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.1007/s40264-020-00926-3

    authors: Jackson DJ,Korn S,Mathur SK,Barker P,Meka VG,Martin UJ,Zangrilli JG

    更新日期:2020-05-01 00:00:00

  • Prevalence of potentially severe drug-drug interactions in ambulatory patients with dyslipidaemia receiving HMG-CoA reductase inhibitor therapy.

    abstract:BACKGROUND:Drug-drug interactions (DDIs) are a well known risk factor for adverse drug reactions. HMG-CoA reductase inhibitors ('statins') are a cornerstone in the treatment of dyslipidaemia and patients with dyslipidaemia are concomitantly treated with a variety of additional drugs. Since DDIs are associated with adve...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.2165/00002018-200528030-00007

    authors: Rätz Bravo AE,Tchambaz L,Krähenbühl-Melcher A,Hess L,Schlienger RG,Krähenbühl S

    更新日期:2005-01-01 00:00:00

  • Newer antiepileptic drugs. Towards an improved risk-benefit ratio.

    abstract::Epilepsy is one of the most common neurological disorders. Even though existing antiepileptic drugs can render 80% of newly diagnosed patients seizure free, a significant number of patients have chronic intractable epilepsy causing disability with considerable socioeconomic implications. There is, therefore, a need fo...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-199411010-00005

    authors: Patsalos PN,Sander JW

    更新日期:1994-07-01 00:00:00

  • All-Cause Mortality Associated with Tramadol Use: A Case-Crossover Study.

    abstract:INTRODUCTION:Although the mortality risk associated with tramadol use in children has triggered the revision of tramadol drug labeling, the mortality risk in adults has not been thoroughly explored. OBJECTIVE:The objective of this study was to evaluate whether tramadol use is associated with mortality in various risk ...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.1007/s40264-018-00786-y

    authors: Jeong S,Tchoe HJ,Li J,Shin JY

    更新日期:2019-06-01 00:00:00

  • Today's challenges in pharmacovigilance: what can we learn from epoetins?

    abstract::Highly publicized safety issues of medicinal products in recent years and the accompanying political pressure have forced both the US FDA and the European Medicines Agency (EMA) to implement stronger regulations concerning pharmacovigilance. These legislative changes demand more proactive risk management strategies of...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/11586350-000000000-00000

    authors: Ebbers HC,Mantel-Teeuwisse AK,Moors EH,Schellekens H,Leufkens HG

    更新日期:2011-04-01 00:00:00

  • A risk-benefit assessment of anti-obesity drugs.

    abstract::This review evaluates the benefits and potential health risks of the currently used drugs that are approved for the pharmacological treatment of obesity. Analysis of several long term clinical trials indicates that all of these drugs are efficient in reducing excess bodyweight, and that the majority of them allow the ...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-199920020-00003

    authors: Kolanowski J

    更新日期:1999-02-01 00:00:00

  • Paraquat poisoning. An overview of the current status.

    abstract::Paraquat is a bipyridyl compound with no known chronic toxicity or teratogenicity. It is poorly absorbed when inhaled, but causes severe illness when ingested orally, death usually occurring within 2 days of ingestion of 50 mg/kg. At lower doses death may be delayed for several weeks. The toxic compound accumulates in...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-199005040-00002

    authors: Bismuth C,Garnier R,Baud FJ,Muszynski J,Keyes C

    更新日期:1990-07-01 00:00:00

  • Safety aspects of parenteral iron in patients with end-stage renal disease.

    abstract::Absolute and functional iron deficiency is the most common cause of epoetin (recombinant human erythropoietin) hyporesponsiveness in renal failure patients. Diagnostic procedures for determining iron deficiency include measurement of serum iron levels, serum ferritin levels, saturation of transferrin and percentage of...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-199717040-00004

    authors: Sunder-Plassmann G,Hörl WH

    更新日期:1997-10-01 00:00:00

  • Association between leukotriene-modifying agents and suicide: what is the evidence?

    abstract::The US FDA has issued safety alerts and required manufacturers of leukotriene-modifying agents (LTMAs), including montelukast, zafirlukast and zileuton, to include suicide and neuropsychiatric events as a precaution in the drug label. This paper reviews the existing evidence on the potential association between the LT...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/11587260-000000000-00000

    authors: Schumock GT,Lee TA,Joo MJ,Valuck RJ,Stayner LT,Gibbons RD

    更新日期:2011-07-01 00:00:00

  • Long-Term Safety and Efficacy of Fecal Microbiota Transplant in Active Ulcerative Colitis.

    abstract:INTRODUCTION AND OBJECTIVE:The therapeutic role of fecal microbiota transplantation in ulcerative colitis varies across different reports. This study aims to evaluate the long-term safety and efficacy of a strategy called step-up fecal microbiota transplantation for ulcerative colitis. METHODS:Two clinical trials (NCT...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.1007/s40264-019-00809-2

    authors: Ding X,Li Q,Li P,Zhang T,Cui B,Ji G,Lu X,Zhang F

    更新日期:2019-07-01 00:00:00

  • Hydroxyurea in the treatment of HIV infection: clinical efficacy and safety concerns.

    abstract::Data from basic science and clinical studies suggest that hydroxyurea (hydroxycarbamide)-based regimens are effective treatment options for patients with HIV at various stages of disease. In vitro studies of HIV-infected lymphocytes have shown that hydroxyurea: (i) inhibits viral DNA synthesis; (ii) synergistically in...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-200326090-00002

    authors: Lisziewicz J,Foli A,Wainberg M,Lori F

    更新日期:2003-01-01 00:00:00

  • Correction to: Medication Errors: A Characterisation of Spontaneously Reported Cases in EudraVigilance.

    abstract::In the original publication of the article, the trend line for non-EEA cases in figure 4 is incorrect. In this correction, the original Fig. 4 (Fig. 1) and the correct Fig. 4 (Fig. 2) are published. ...

    journal_title:Drug safety

    pub_type: 杂志文章,已发布勘误

    doi:10.1007/s40264-018-0700-0

    authors: Newbould V,Le Meur S,Goedecke T,Kurz X

    更新日期:2018-12-01 00:00:00

  • Mortality associated with attention-deficit hyperactivity disorder (ADHD) drug treatment: a retrospective cohort study of children, adolescents and young adults using the general practice research database.

    abstract:BACKGROUND:Following reports of sudden death in patients taking medication to treat attention-deficit hyperactivity disorder (ADHD), this study aimed to identify cases of death in patients prescribed stimulants and atomoxetine and to determine any association between these and sudden death. METHOD:The UK General Pract...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.2165/11317630-000000000-00000

    authors: McCarthy S,Cranswick N,Potts L,Taylor E,Wong IC

    更新日期:2009-01-01 00:00:00

  • Validation of multivariate outlier detection analyses used to identify potential drug-induced liver injury in clinical trial populations.

    abstract:BACKGROUND:Potential severe liver injury is identified in clinical trials by ALT >3 × upper limits of normal (ULN) and total bilirubin >2 × ULN, and termed 'Hy's Law' by the US FDA. However, there is limited evidence or validation of these thresholds in clinical trial populations. Using liver chemistry data from clinic...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.1007/BF03261982

    authors: Lin X,Parks D,Painter J,Hunt CM,Stirnadel-Farrant HA,Cheng J,Menius A,Lee K

    更新日期:2012-10-01 00:00:00

  • Reports of sexual disorders related to serotonin reuptake inhibitors in the French pharmacovigilance database: an example of underreporting.

    abstract:BACKGROUND:Depressive disorders and use of antidepressants are associated with adverse effects on sexual function. In pharmacoepidemiological studies, sexual disorders are reported by more than 50 % of patients taking serotonin reuptake inhibitors (SRIs). OBJECTIVE:The aim of this study was to determine the reporting ...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.1007/s40264-013-0069-z

    authors: Trenque T,Maura G,Herlem E,Vallet C,Sole E,Auriche P,Drame M

    更新日期:2013-07-01 00:00:00

  • Traceability of Biologics in The Netherlands: An Analysis of Information-Recording Systems in Clinical Practice and Spontaneous ADR Reports.

    abstract:INTRODUCTION AND OBJECTIVE:Pharmacovigilance requirements for biologics mandate that EU Member States shall ensure that any biologic that is the subject of a suspected adverse drug reaction (ADR) is identifiable by brand name and batch number. Recent studies showed that brand name identification is well established, wh...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.1007/s40264-015-0383-8

    authors: Klein K,Scholl JH,Vermeer NS,Broekmans AW,Van Puijenbroek EP,De Bruin ML,Stolk P

    更新日期:2016-02-01 00:00:00

  • Is gender a risk factor for adverse drug reactions? The example of drug-induced long QT syndrome.

    abstract::Drug-induced torsade de pointes is a rare life-threatening adverse drug reaction (ADR) which is strongly influenced by gender. Drugs that prolong cardiac repolarisation include antiarrhythmics, gastrokinetics, antipsychotics, antihistamines and antibacterials. Such drugs share the potential to block cardiac voltage-ga...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-200124080-00002

    authors: Drici MD,Clément N

    更新日期:2001-01-01 00:00:00

  • Benefit-risk assessment of transdermal fentanyl for the treatment of chronic pain.

    abstract::Transdermal fentanyl is effective and well tolerated for the treatment of chronic pain caused by malignancy and non-malignant conditions when administered according to the manufacturer's recommendations. Compared with oral opioids, the advantages of transdermal fentanyl include a lower incidence and impact of adverse ...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-200326130-00004

    authors: Kornick CA,Santiago-Palma J,Moryl N,Payne R,Obbens EA

    更新日期:2003-01-01 00:00:00

  • Discourse on safe drug use: symbolic logics and ethical aspects.

    abstract::Drug safety is not a matter for healthcare professionals alone. Patients are also involved, at three different levels: (i) in the behaviours patients adopt to reduce the adverse effects of the drugs; (ii) in regard to what some doctors say to their patients about drug risks; and (iii) in what the pharmaceutical indust...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/11538320-000000000-00000

    authors: Fainzang S

    更新日期:2010-08-01 00:00:00

  • Pharmacists' interventions in prescribing errors at hospital discharge: an observational study in the context of an electronic prescribing system in a UK teaching hospital.

    abstract:BACKGROUND:Pharmacists have an essential role in improving drug usage and preventing prescribing errors (PEs). PEs at the interface of care are common, sometimes leading to adverse drug events (ADEs). This was the first study to investigate, using a computerized search method, the number, types, severity, pharmacists' ...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.2165/11538310-000000000-00000

    authors: Abdel-Qader DH,Harper L,Cantrill JA,Tully MP

    更新日期:2010-11-01 00:00:00

  • Ipilimumab-Induced Enterocolitis: A Systematic Review and Meta-Analysis.

    abstract:INTRODUCTION:Checkpoint inhibitor drugs including ipilimumab have been reported to induce intestinal injury. OBJECTIVE:We aimed to evaluate the risk of chronic (> 6 weeks) enterocolitis following ipilimumab administration, and the likelihood that an enteritis vs colitis or enterocolitis is seen. PATIENTS AND METHODS:...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.1007/s40264-020-00979-4

    authors: Witges K,Shafer LA,Zarychanski R,Abou-Setta AM,Rabbani R,Dingwall O,Bernstein CN

    更新日期:2020-12-01 00:00:00